regulatory
confidence high
sentiment negative
materiality 0.62
Passage Bio gets Nasdaq deficiency notice; stockholders' equity $50K vs $2.5M minimum
Passage BIO, Inc.
- Nasdaq Rule 5550(b)(1) requires $2.5M minimum stockholders' equity; Passage Bio reported $50,000 at Sept 30, 2026 and fails the market-value and net-income alternatives.
- Letter from Nasdaq Listing Qualifications dated Nov 12, 2026 has no immediate effect; PASG continues trading on the Nasdaq Capital Market.
- Company expects the pending Remix Therapeutics mergers (A&R agreement dated Sept 2, 2026, amended Oct 5, 2026) to restore compliance on close.
- Upon closing, Passage Bio will rename itself Remix Therapeutics, Inc. and trade under symbol RMTX; Nasdaq listing approval is a remaining closing condition.
- If the mergers are not completed within the Nasdaq-provided period, the company intends to submit a plan to regain compliance.
Featured in Daily 8-K Digest
Selected #5 for 2026-11-18.
Read digest